Darexaban (YM150) is a potent, selective, and orally active factor Xa (FXa) inhibitor. It exhibits high selectivity against other related serine proteases such as trypsin, thrombin, and kallikrein, and possesses anticoagulant and antithrombotic effects.
- Potent, selective, and orally active factor Xa (FXa) inhibitor.
- Inhibits FXa activity in plasma.
- Prolongs prothrombin time (PT).
- Reduces mortality rate in a pulmonary thromboembolism mouse model.
- Decreases thrombus protein content in a FeCl3-induced venous thrombosis mouse model.
- Exhibits high selectivity against trypsin, thrombin, and kallikrein.
- Possesses anticoagulant and antithrombotic effects.